A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

NCT06118866 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

192

Enrollment

INDUSTRY

Sponsor class

Conditions

Androgenetic Alopecia

Interventions

DRUG: placebo-Q2W
DRUG: HMI-115-120mg-Q4W
DRUG: HMI-115-240mg-Q4W
DRUG: HMI-115, 240mg-Q2W

Sponsor

Hope Medicine (Nanjing) Co., Ltd